<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">clinvest</journal-id><journal-title-group><journal-title xml:lang="ru">Качественная клиническая практика</journal-title><trans-title-group xml:lang="en"><trans-title>Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2588-0519</issn><issn pub-type="epub">2618-8473</issn><publisher><publisher-name>ООО «Издательство ОКИ</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.37489/2588-0519-2020-3-52-60</article-id><article-id custom-type="elpub" pub-id-type="custom">clinvest-506</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL TRIALS</subject></subj-group></article-categories><title-group><article-title>Прагматические клинические исследования</article-title><trans-title-group xml:lang="en"><trans-title>Pragmatic clinical trials</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шевченко</surname><given-names>О. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Shevchenko</surname><given-names>O. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шевченко Ольга Романовна - аспирант кафедры клинической фармакологии и доказательной медицины</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Shevchenko Olga R. - Post-graduate student, Department of Clinical Pharmacology and Evidence-Based Medicine</p><p>St. Petersburg</p></bio><email xlink:type="simple">o.r.shevchenko@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1919-2909</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Колбин</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolbin</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Колбин Алексей Сергеевич - д. м. н., профессор, заведующий кафедрой клинической фармакологии и доказательной медицины, ФГБОУ ВО ПСПбГМУ им И.П. Павлова Минздрава России; профессор кафедры фармакологии медицинского факультета СПбГУ</p><p>SPIN-код: 7966-0845</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Kolbin Alexey S. - D. Sci. in Medicine, Professor, Head of the Department of Clinical Pharmacology and Evidence-Based Medicine, FSBEI HE I.P. Pavlov SPbSMU MOH Russia; Professor of the Department of Pharmacology, Medical Faculty, SPbSU</p><p>SPIN code: 7966-0845</p><p>St. Petersburg</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им академика И.П. Павлова» Министерства Здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>FSBEI HE I.P. Pavlov SPbSMU MOH Russia</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им академика И.П. Павлова» Министерства Здравоохранения Российской Федерации; &#13;
ГБОУ ВО «Санкт-Петербургский государственный университет»,</institution><country>Россия</country></aff><aff xml:lang="en"><institution>FSBEI HE I.P. Pavlov SPbSMU MOH Russia; &#13;
FSBEI HE “Saint-Petersburg State University”</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>26</day><month>09</month><year>2020</year></pub-date><volume>0</volume><issue>3</issue><fpage>52</fpage><lpage>60</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шевченко О.Р., Колбин А.С., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Шевченко О.Р., Колбин А.С.</copyright-holder><copyright-holder xml:lang="en">Shevchenko O.R., Kolbin A.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.clinvest.ru/jour/article/view/506">https://www.clinvest.ru/jour/article/view/506</self-uri><abstract><p>Прагматические исследования позволяют объединить преимущества наблюдательного исследования в реальной клинической практике с научной строгостью рандомизированного клинического исследования (РКИ) и тем самым дать более эффективные ответы на вопросы реальной клинической практики.</p><sec><title>Цель</title><p>Цель. Оценка различий в проведении классических РКИ и прагматических клинических исследований (ПКИ), а также анализ особенностей, касающихся их проведения на разных этапах.</p></sec><sec><title>Методология</title><p>Методология. Проведён анализ ряда публикаций в период с 1999 по 2017 гг. на предмет выявления данных, посвящённых ПКИ.</p></sec><sec><title>Результаты</title><p>Результаты. В проведении классических РКИ и ПКИ имеются существенные различия. Прежде всего, в ПКИ используют более гибкие критерии включения и отличается подход к выбору центра исследования. Также процедура получения информированного согласия имеет существенные отличия от таковой при классическом РКИ; предложены альтернативные варианты, однако единый подход пока не выработан. При проведении ПКИ требуются минимальные вмешательства монитора в рутинную медицинскую практику, что, однако, может привести к нарушению сбора отчётности. Вариантом решения может стать удалённый сбор данных.</p></sec><sec><title>Выводы</title><p>Выводы. ПКИ представляют собой огромный потенциал для исследования эффективности лекарственных препаратов в условиях реальной клинической практики. Однако, несмотря на значительное увеличение количества таких исследований, всё ещё существует достаточное количество моментов, требующих урегулирования.</p></sec></abstract><trans-abstract xml:lang="en"><p>Pragmatic clinical trials (PCTs) allow combining the advantages of observational trials in real-world evidence with the scientific rigor of randomized clinical trials (RCTs), and thereby provide more effective answers to questions of real-world evidence.</p><sec><title>Aim</title><p>Aim. Assessment of differences in conducting RCTs and PCTs, as well as analysis of the features related to conducting PCTs at different stages.</p></sec><sec><title>Methods</title><p>Methods. An analysis of publications in the period from 1999 to 2017 was conducted to identify data on PCTs.</p></sec><sec><title>Results</title><p>Results. There are significant differences in conducting classic RCTs and PCTs. First, PCTs use more flexible inclusion criteria and differ in the approach to choosing an investigator’s site. Also, the procedure for obtaining informed consent has significant differences from that of classical RCTs; alternative options are proposed but a unified approach has not yet been developed. When conducting PCTs, monitor intervention should be minimal in order not to interfere in the routine therapy, which, however, can lead to a violation of reporting. A possible solution may be remote data collection.</p></sec><sec><title>Conclusion</title><p>Conclusion. PCTs represent a huge potential for studying the effectiveness of drugs in real-world evidence. However, despite a significant increase in the number of such trials, there are still a sufficient number of points that need to be resolved.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>клинические исследования</kwd><kwd>прагматические клинические исследования</kwd><kwd>реальная клиническая практика</kwd><kwd>исследования сравнительной эффективности</kwd></kwd-group><kwd-group xml:lang="en"><kwd>clinical trials</kwd><kwd>pragmatic clinical trials</kwd><kwd>real-world evidence</kwd><kwd>comparative effectiveness assessment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Управление клиническими исследованиями / под общ. ред. Белоусова Д. Ю., Зырянова С. К., Колбина А. С. — 1-е изд. — М.: Буки Веди: Издательство ОКИ, 2017. — 676 с.: ил.</mixed-citation><mixed-citation xml:lang="en">Upravlenie klinicheskimi issledovaniyami / pod obshch. red. Belousova DYU, Zyryanova SK, Kolbina AS. — 1-e izd. — M.: Buki Vedi: Izdatel’stvo OKI, 2017. (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">FDA. Framework for FDA’s real-world evidence program. 2018. [cited 2020 Jul 25]. Available from: https://www.fda.gov/media/120060/download</mixed-citation><mixed-citation xml:lang="en">FDA. Framework for FDA’s real-world evidence program. 2018. [cited 2020 Jul 25]. Available from: https://www.fda.gov/media/120060/download</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Cochrane AL. Effectiveness and efficiency: random reflection on health services. — London: Nuffield Provincial Hospitals Trust. 1972. [cited 2020 Jul 25]. Available from: https://www.nuffieldtrust.org.uk/files/2017-01/effectiveness-and-efficiency-web-final.pdf DOI: 10.1016/S0033-3506(73)80082-4</mixed-citation><mixed-citation xml:lang="en">Cochrane AL. Effectiveness and efficiency: random reflection on health services. — London: Nuffield Provincial Hospitals Trust. 1972. [cited 2020 Jul 25]. Available from: https://www.nuffieldtrust.org.uk/files/2017-01/effectiveness-and-efficiency-web-final.pdf DOI: 10.1016/S0033-3506(73)80082-4</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Wang X, et al. Identification and mapping of worldwide sources of generic real-world data. Pharmacoepidemiol Drug Saf. 2019;28(7):899-905. DOI: 10.1002/pds.4782</mixed-citation><mixed-citation xml:lang="en">Wang X, et al. Identification and mapping of worldwide sources of generic real-world data. Pharmacoepidemiol Drug Saf. 2019;28(7):899-905. DOI: 10.1002/pds.4782</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. BMJ. 2016;352:i493. DOI: 10.1136/bmj.i493</mixed-citation><mixed-citation xml:lang="en">Hemkens LG, Contopoulos-Ioannidis DG, Ioannidis JP. Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey. BMJ. 2016;352:i493. DOI: 10.1136/bmj.i493</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Zuidgeest MGP, Goetz I, Groenwold RHH, et al. Series: Pragmatic trials and real world evidence: Paper 1. Introduction. Journal of Clinical Epidemiology. 2017;88:7-13. DOI:10.1016/j.jclinepi.2016.12.023</mixed-citation><mixed-citation xml:lang="en">Zuidgeest MGP, Goetz I, Groenwold RHH, et al. Series: Pragmatic trials and real world evidence: Paper 1. Introduction. Journal of Clinical Epidemiology. 2017;88:7-13. DOI:10.1016/j.jclinepi.2016.12.023</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Schwartz D, Lellouch J. Explanatory and Pragmatic Attitudes in Therapeutical Trials. J. Chron. Dis. 1967;20:637-648.</mixed-citation><mixed-citation xml:lang="en">Schwartz D, Lellouch J. Explanatory and Pragmatic Attitudes in Therapeutical Trials. J. Chron. Dis. 1967;20:637-648.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337;a2390. DOI:10.1136/bmj.a2390</mixed-citation><mixed-citation xml:lang="en">Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ. 2008;337;a2390. DOI:10.1136/bmj.a2390</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62(5):464-75. DOI: 10.1016/j.jclinepi.2008.12.011</mixed-citation><mixed-citation xml:lang="en">Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol. 2009;62(5):464-75. DOI: 10.1016/j.jclinepi.2008.12.011</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Loudon K, Treweek S, Sullivan F, et al. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147. DOI: 10.1136/bmj.h2147</mixed-citation><mixed-citation xml:lang="en">Loudon K, Treweek S, Sullivan F, et al. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147. DOI: 10.1136/bmj.h2147</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Worsley SD, Rengerink KO, Irving EA, et al. Series: Pragmatic Trials and Real World Evidence: Paper 2. Setting, Sites, and Investigator Selection. Journal of Clinical Epidemiology. 2017;88:14-20. DOI: 10.1016/j.jclinepi.2017.05.003</mixed-citation><mixed-citation xml:lang="en">Worsley SD, Rengerink KO, Irving EA, et al. Series: Pragmatic Trials and Real World Evidence: Paper 2. Setting, Sites, and Investigator Selection. Journal of Clinical Epidemiology. 2017;88:14-20. DOI: 10.1016/j.jclinepi.2017.05.003</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Donovan JL, Paramasivan S, de Salis I, et al. Clear obstacles and hidden challenges: understanding recruiter perspectives in six pragmatic randomised controlled trials. Trials. 2014; 15:5 [cited 2020 Jul 25]. Available from: https://trialsjournal.biomedcentral.com/track/pdf/10.1186/1745-6215-15-5</mixed-citation><mixed-citation xml:lang="en">Donovan JL, Paramasivan S, de Salis I, et al. Clear obstacles and hidden challenges: understanding recruiter perspectives in six pragmatic randomised controlled trials. Trials. 2014; 15:5 [cited 2020 Jul 25]. Available from: https://trialsjournal.biomedcentral.com/track/pdf/10.1186/1745-6215-15-5</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kennedy-Martin T, Curtis S, Faries D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495. DOI: 10.1186/s13063-015-1023-4</mixed-citation><mixed-citation xml:lang="en">Kennedy-Martin T, Curtis S, Faries D, et al. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495. DOI: 10.1186/s13063-015-1023-4</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Welch MJ, Larry RC, Miller JE, et al. The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials. Clinical trials. 2015;12:503-510. DOI: 10.1177/1740774515597701</mixed-citation><mixed-citation xml:lang="en">Welch MJ, Larry RC, Miller JE, et al. The ethics and regulatory landscape of including vulnerable populations in pragmatic clinical trials. Clinical trials. 2015;12:503-510. DOI: 10.1177/1740774515597701</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Council for International Organizations of Medical Sciences. International Ethical Guidelines for Biomedical Research Involving Human Subjects. CIOMS, Geneva, Switzerland, 2002 [cited 2020 Jul 25]. Available at: https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf</mixed-citation><mixed-citation xml:lang="en">Council for International Organizations of Medical Sciences. International Ethical Guidelines for Biomedical Research Involving Human Subjects. CIOMS, Geneva, Switzerland, 2002 [cited 2020 Jul 25]. Available at: https://cioms.ch/wp-content/uploads/2017/01/WEB-CIOMS-EthicalGuidelines.pdf</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol. 2009;62(5):499-505. DOI: 10.1016/j.jclinepi.2009.01.012</mixed-citation><mixed-citation xml:lang="en">Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Clin Epidemiol. 2009;62(5):499-505. DOI: 10.1016/j.jclinepi.2009.01.012</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zuidgeest MGP, Welsing PMJ, G JMW van Thiel, et al. Series: Pragmatic trials and real world evidence: Paper 5. Usual care and real life comparators. Journal of Clinical Epidemiology. 2017;90;92-98. DOI: 10.1016/j.jclinepi.2017.07.001</mixed-citation><mixed-citation xml:lang="en">Zuidgeest MGP, Welsing PMJ, G JMW van Thiel, et al. Series: Pragmatic trials and real world evidence: Paper 5. Usual care and real life comparators. Journal of Clinical Epidemiology. 2017;90;92-98. DOI: 10.1016/j.jclinepi.2017.07.001</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ross S, Grant A, Counsell CE, et al. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol. 1999;52(12):1143-1156. DOI: 10.1016/S0895-4356(99)00141-9</mixed-citation><mixed-citation xml:lang="en">Ross S, Grant A, Counsell CE, et al. Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol. 1999;52(12):1143-1156. DOI: 10.1016/S0895-4356(99)00141-9</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">T-P van Staa, Goldacre B, Gulliford M, et al. Pragmatic randomised trials using routine electronic health records: putting them to the test. BMJ. 2012;344:e55. DOI: 10.1136/bmj.e55</mixed-citation><mixed-citation xml:lang="en">T-P van Staa, Goldacre B, Gulliford M, et al. Pragmatic randomised trials using routine electronic health records: putting them to the test. BMJ. 2012;344:e55. DOI: 10.1136/bmj.e55</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">McKinney RE, Beskow LM, Ford DE. Use of altered informed consent in pragmatic clinical research. Clin Trials. 2015;12(5):494-502. DOI:10.1177/1740774515597688</mixed-citation><mixed-citation xml:lang="en">McKinney RE, Beskow LM, Ford DE. Use of altered informed consent in pragmatic clinical research. Clin Trials. 2015;12(5):494-502. DOI:10.1177/1740774515597688</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SYH, Miller FG. Informed consent for pragmatic trials — the integrated consent model. N Engl J Med. 2014;370(8):769-772. DOI: 10.1056/NEJMhle1312508</mixed-citation><mixed-citation xml:lang="en">Kim SYH, Miller FG. Informed consent for pragmatic trials — the integrated consent model. N Engl J Med. 2014;370(8):769-772. DOI: 10.1056/NEJMhle1312508</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Wendler D. “Targeted” Consent for Pragmatic Clinical Trials. JGIM. 2015;30;679-682. DOI: 10.1007/s11606-014-3169-2</mixed-citation><mixed-citation xml:lang="en">Wendler D. “Targeted” Consent for Pragmatic Clinical Trials. JGIM. 2015;30;679-682. DOI: 10.1007/s11606-014-3169-2</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kalkman S, GJMW van Thiel, Zuidgeest M, et al. Series: Pragmatic trials and real world evidence: Paper 4. Informed consent. Journal of clinical epidemiology. 2017;89:181-187. DOI: 10.1016/j.jclinepi.2017.03.019</mixed-citation><mixed-citation xml:lang="en">Kalkman S, GJMW van Thiel, Zuidgeest M, et al. Series: Pragmatic trials and real world evidence: Paper 4. Informed consent. Journal of clinical epidemiology. 2017;89:181-187. DOI: 10.1016/j.jclinepi.2017.03.019</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Faden R, Kass N, Whicher D, et al. Ethics and informed consent for comparative effectiveness research with prospective electronic clinical data. Med Care. 2013;51(8 Suppl 3):S53-S57. DOI: 10.1097/MLR.0b013e31829b1e4b</mixed-citation><mixed-citation xml:lang="en">Faden R, Kass N, Whicher D, et al. Ethics and informed consent for comparative effectiveness research with prospective electronic clinical data. Med Care. 2013;51(8 Suppl 3):S53-S57. DOI: 10.1097/MLR.0b013e31829b1e4b</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Truog RD, Robinson W, Randolph A, et al. Is informed consent always necessary for randomized, controlled trials? N Engl J Med. 1999;340:804-807. DOI: 10.1056/NEJM199903113401013</mixed-citation><mixed-citation xml:lang="en">Truog RD, Robinson W, Randolph A, et al. Is informed consent always necessary for randomized, controlled trials? N Engl J Med. 1999;340:804-807. DOI: 10.1056/NEJM199903113401013</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Irving E et al. Series: Pragmatic trials and real world evidence: Paper 7. Safety, quality and monitoring. Journal of clinical epidemiology. 2017;91;6-12. DOI: 10.1016/j.jclinepi.2017.05.004</mixed-citation><mixed-citation xml:lang="en">Irving E et al. Series: Pragmatic trials and real world evidence: Paper 7. Safety, quality and monitoring. Journal of clinical epidemiology. 2017;91;6-12. DOI: 10.1016/j.jclinepi.2017.05.004</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">JAMA Deputy Editor Edward Livingston, MD, discusses Pragmatic Trials: Practical Answers to «Real-world» Questions with Harold C. Sox, MD, of PCORI [cited 2020 Jul 25]. Available from: https://edhub.ama-assn.org/jn-learning/audio-player/18519479?utm_source=fbpage&amp;utm_medium=social_jama&amp;utm_term=3448260363&amp;utm_campaign=article_alert&amp;linkId=91852989</mixed-citation><mixed-citation xml:lang="en">JAMA Deputy Editor Edward Livingston, MD, discusses Pragmatic Trials: Practical Answers to «Real-world» Questions with Harold C. Sox, MD, of PCORI [cited 2020 Jul 25]. Available from: https://edhub.ama-assn.org/jn-learning/audio-player/18519479?utm_source=fbpage&amp;utm_medium=social_jama&amp;utm_term=3448260363&amp;utm_campaign=article_alert&amp;linkId=91852989</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">van Staa T-P, Dyson L, McCann G, et al. The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. Southampton (UK): NIHR Journals Library. Health Technol Assess. 2014 Jul;18(43):1-146. DOI: 10.3310/hta18430</mixed-citation><mixed-citation xml:lang="en">van Staa T-P, Dyson L, McCann G, et al. The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. Southampton (UK): NIHR Journals Library. Health Technol Assess. 2014 Jul;18(43):1-146. DOI: 10.3310/hta18430</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Uren SC, Kirkman MB, Dalton B, et al. Reducing clinical trial monitoring resource allocation and costs through remote access to electronic medical records. Journal of oncology practice. 2013;9(1):e13-6. DOI: 10.1200/JOP.2012.000666</mixed-citation><mixed-citation xml:lang="en">Uren SC, Kirkman MB, Dalton B, et al. Reducing clinical trial monitoring resource allocation and costs through remote access to electronic medical records. Journal of oncology practice. 2013;9(1):e13-6. DOI: 10.1200/ JOP.2012.000666</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Coronado GD, Vollmer WM, Petrik A, et al. Strategies and Opportunities to STOP Colon Cancer in Priority Populations: design of a cluster-randomized pragmatic trial. Contemp Clin Trials. 2014;38(2):344-9. DOI: 10.1016/j.cct.2014.06.006</mixed-citation><mixed-citation xml:lang="en">Coronado GD, Vollmer WM, Petrik A, et al. Strategies and Opportunities to STOP Colon Cancer in Priority Populations: design of a cluster-randomized pragmatic trial. Contemp Clin Trials. 2014;38(2):344-9. DOI: 10.1016/j.cct.2014.06.006</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">2019 Annual Report: A Pragmatic Approach to Benefit an Understudied Population [cited 2020 Jul 25]. Available from: https://dcri.org/2019-annual-report-a-pragmatic-approach-to-benefit-an-understudied-population/</mixed-citation><mixed-citation xml:lang="en">2019 Annual Report: A Pragmatic Approach to Benefit an Understudied Population [cited 2020 Jul 25]. Available from: https://dcri.org/2019-annual-report-a-pragmatic-approach-to-benefit-an-understudied-population/</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Datta S. HEARTLINE: A 180,000 Patient-Strong, Pragmatic, Real World Randomized Trial Assesses the Prowess of Apple Technology in Afib Diagnosis and Improvement of Hard Outcomes. Cardiology now. 2019 March [cited 2020 Jul 25]. Available from: https://cardiologynownews.org/ heartline-a-180000-patient-strong-pragmatic-real-world-trial-assess-the-prowess-of-apple-technology-in-afib-diagnosis-and-improvement-of-hard-outcomes/</mixed-citation><mixed-citation xml:lang="en">Datta S. HEARTLINE: A 180,000 Patient-Strong, Pragmatic, Real World Randomized Trial Assesses the Prowess of Apple Technology in Afib Diagnosis and Improvement of Hard Outcomes. Cardiology now. 2019 March [cited 2020 Jul 25]. Available from: https://cardiologynownews.org/ heartline-a-180000-patient-strong-pragmatic-real-world-trial-assess-the-prowess-of-apple-technology-in-afib-diagnosis-and-improvement-of-hard-outcomes/</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
